World reference laboratory confirms efficacy against pandemic SAT1 topotype III variant;
first independent global evidence of cross-protection
As the SAT1 topotype III strain of foot-and-mouth disease (FMD) continues to expand across Southern Africa, the Middle East, Europe, and Asia, veterinary authorities and livestock producers face increasing pressure to strengthen prevention and outbreak preparedness strategies. The rapidly evolving nature of the virus, combined with the severe economic impact of outbreaks, makes access to scientifically validated vaccines a critical component of disease-control programs.
An outbreak of FMD imposes devastating economic consequences, including export market closures, mandatory quarantines, livestock movement restrictions, and losses estimated between USD 2 billion and USD 5 billion per affected country, according to the World Organization for Animal Health (WOAH).
Against this backdrop, a heterologous challenge study conducted by Wageningen Bioveterinary Research has validated that BIOAFTOGEN® SAT1, a vaccine produced by the Argentine company Biogénesis Bagó, provides 100% protection against the SAT1 topotype III strain when administered in a two-dose regimen and 86% protection with a single dose. Significantly, this represents the first independent global validation of cross-protection against the pandemic SAT1 topotype III variant currently circulating across multiple regions of the world.
The findings are particularly significant because the vaccine was tested against the SAT1/LEB/8/2025 strain (topotype III), a viral variant different from the one used in its manufacture. The results therefore demonstrate effectiveness against the genetic diversity circulating in endemic regions. For governments, veterinarians, and livestock producers across Africa, the Middle East, and Asia, where SAT1 FMD remains an active threat, the study provides scientific validation of a reliable disease-control tool backed by rigorous independent testing.
The vaccine’s high potency, previously confirmed at more than 128 PD50 in testing at Wageningen University, proved decisive. While vaccine matching assays (R1 values) provide only indirect indicators of potential efficacy, challenge testing under controlled conditions remains the scientific gold standard for demonstrating real-world protection.
“These results provide governments, farmers and organizations with a proven tool in the fight against FMD”, said Rodolfo Bellinzoni, FMD Scientific Director at Biogénesis Bagó. “This is not only a scientifically validated vaccine; it is also backed by a company that has demonstrated its ability to respond to large-scale animal health emergencies—and now has independent evidence of protection against the pandemic strain threatening the region.”
Biogénesis Bagó: experience forged in crisis
Behind BIOAFTOGEN® SAT1 is Biogénesis Bagó, an Argentine company with more than 70 years of experience responding to FMD outbreaks worldwide. Its leadership has been established thanks to its production and operational capacity which has been put to the test on many occasions and has allowed the company to provide world class vaccines on record time to FMD emergencies such as Taiwan (1997), South Korea (2016), and Israel (2026) among others. A notable example occurred during Argentina’s 2001 FMD epidemic, when the company produced and distributed more than 120 million vaccine doses in only 11 months, helping contain the outbreak and enabling the country to regain FMD-free status in record time. This proven ability to respond under pressure is precisely what affected regions may require today.
Biogénesis Bagó is one of the few companies worldwide capable of producing vaccines against all seven FMD serotypes. This capability has positioned the company as a supplier of antigen banks for Brazil, the United States, Argentina, South Korea, Taiwan, and Canada. Its combination of crisis-management experience, technical expertise, and independent validation of cross-protection against the pandemic SAT1 topotype III strain makes it a strategic partner for regions where the strain remains an active threat.
Scientific validation from a world reference laboratory
The study was conducted by Wageningen Bioveterinary Research, accredited as the National Reference Laboratory of the Netherlands for notifiable animal diseases and certified by AAALAC for compliance with international animal welfare standards. The laboratory is also approved by FAO/WOAH for biological product validation.
Why the heterologous challenge matters
A homologous challenge demonstrates efficacy against the same virus used to produce the vaccine. A heterologous challenge is scientifically more demanding and far more relevant to real-world conditions, where viruses continuously evolve.
The Wageningen results demonstrate that BIOAFTOGEN® SAT1 is effective against the actual viral variants circulating in affected regions. For veterinarians and animal health authorities, this is particularly significant because it demonstrates that the vaccine is not limited to protection against a single viral isolate, but provides protection across the genetic diversity likely to be encountered in the field.
